Compounded Sema Injectable denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Compounded Semaglutide as Not FDA-Approved

Unlike the UHC cochlear implant denial where "not-FDA-approved" is likely an error, this denial for compounded semaglutide reflects a factually accurate characterization: compounded semaglutide preparations are not FDA-approved finished drug products. Compounding pharmacies are not required to conduct the same clinical trials and manufacturing validation as drug manufacturers, and FDA approval applies to the finished, commercial product — not to pharmacy-compounded formulations of the same active ingredient. Cigna applies this denial consistently and intentionally to exclude coverage of compounded GLP-1 preparations.

## Why It Is Still Appealable

While the factual basis for this denial is accurate, it is not the end of the road. The appeal does not argue that the compound has FDA approval — that would be false. Instead, the strongest appeals argue: (1) the FDA-approved alternative was not available or accessible to this specific patient (documented shortage or formulary exclusion); (2) medical necessity is established for the underlying condition, and the compound is the only accessible option; and (3) applicable guideline organizations endorse the clinical indication for semaglutide, supporting coverage even when the specific formulation is compounded. Some appeals also invoke state laws governing insurer coverage of compounded medications.

## The Federal Appeal Framework

• Internal appeal: File under ERISA Section 503 (employer plans) or ACA Section 2719 (individual/marketplace plans) within the deadline on the denial letter. Request from Cigna the exact policy and criteria applied.
• External review: After exhausting internal appeals, request independent external review under ACA Section 2719 — generally within four months of the final denial. External reviewers assess whether denial was consistent with generally accepted medical practice, which can override coverage exclusions in limited circumstances.
• State law overlay: If your plan is fully insured (not self-funded), your state's insurance laws govern in addition to federal law. Some states have laws or regulations addressing compounded drug coverage that may supplement your appeal rights.
• Expedited option: Request expedited review if delay poses immediate clinical risk.

## Documentation to Gather

• FDA shortage documentation: Print the current FDA drug shortage database entry for the relevant branded semaglutide product at the time the compound was prescribed. This is typically the pivotal piece of evidence.
• Formulary barrier documentation: Evidence that the branded FDA-approved product is excluded from your plan's formulary, requires prior authorization that was denied, or carries cost-sharing that creates a practical access barrier.
• Diagnosis and clinical severity: Chart documentation of the underlying condition and its severity, establishing that pharmacological treatment is medically warranted.
• Prior treatment history: Timeline of prior pharmacological treatments with dates, outcomes, and reasons for discontinuation.
• Prescriber medical-necessity letter: Addressing the not-FDA-approved basis honestly (acknowledging compound status) while asserting medical necessity for the underlying indication and documenting the access barrier to the FDA-approved alternative.

## Criteria-Mapping Structure

Obtain Cigna's compounded drug coverage policy and its GLP-1 coverage policy. Address both:

| Cigna Not-FDA-Approved Criterion | Appeal Response | |---|---| | Compound lacks FDA approval | Acknowledged; appeal argues access barrier to approved alternative | | FDA-approved alternative available | FDA shortage record or formulary exclusion documentation | | Medical necessity for this indication | Prescriber letter citing diagnosis, history, guideline endorsement |

Be precise in the appeal letter: clearly state the patient is not claiming the compound is FDA-approved, but rather that it is the only accessible treatment option for an established medical condition — this framing is more persuasive to both internal reviewers and external IROs.